- Iraj Ali
- Karl Peggs
- % Shareholding
- Number of employees
- Clinical trials
Unless stated all figures at 31 March 2021
Achilles Therapeutics is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell.
Achilles uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, allows individualised treatments to target and destroy tumours without harming healthy tissues.
Achilles has built a world-leading bioinformatics platform to identify clonal neoantigens from each patient’s unique tumour profile. Their proprietary PELEUSTM platform was developed from their co-founder Professor Charles Swanton’s academic TRACERx bioinformatics pipeline and has been validated using Achilles’ exclusive access to the TRACERx sequence data.
- TILs have shown convincing efficacy in solid tumours*
- Leveraging clonal neoantigens to develop specific immunotherapies to increase response rates and reduce risk of relapse
Unmet medical need
- Lung cancer has limited treatment options and is the leading cause of cancer deaths
- 234,000 patient opportunity in non-small cell lung cancer**
- In 2021, over 207,000 patients are expected to be diagnosed with melanoma in the US***
- Highly innovative concept in emerging space
- Complex manufacturing
- Increasing competition
* Source: Rosenberg et al 2011 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131487/pdf/nihms286994.pdf
** Source: https://pubmed.ncbi.nlm.nih.gov/33600992/
The Achilles Therapeutics pipeline
Non-small cell lung cancer